Literature DB >> 28593608

Tumor necrosis factor-α -308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to disease activity, damage, and functional status.

Iman I El Gazzar1, Hanan M Fathy2, Tamer A Gheita3, Abeer M Nour El-Din4, Enas Abdel Rasheed5, Rasha H Bassyouni6, Sanaa A Kenawy7.   

Abstract

The study aims to evaluate the clinical significance of serum levels of tumor necrosis factor alpha (TNF-α) and -308 A/G promoter polymorphism in juvenile idiopathic arthritis (JIA) patients and find any association to the subsets, clinical and laboratory features, disease activity, and damage as well as functional disability. Forty-eight JIA children and 30 controls were included in the present study. Juvenile arthritis disease activity score in 27 joints (JADAS-27) was calculated, juvenile arthritis damage index (JADI) was assessed, and Childhood Health Assessment Questionnaire (CHAQ) measured the functional status. Serum TNF-α was assayed by ELISA and gene (-308) promoter polymorphism was determined by polymerase chain reaction. The 48 JIA children (mean age 11.5 ± 2.8 years) were 13 systemic, 17 oligoarticular, and 18 polyarticular onset. The serum TNF-α was significantly higher in patients (90.4 ± 6.3 ng/ml) compared to control (3.5 ± 2.6 ng/ml) (p < 0.0001) with a tendency to be higher in the polyarticular subtype. All controls had TNF-α -308 GG alleles. The frequency of GG genotype tended to be higher in systemic onset compared to oligoarticular and polyarticular subtypes. The serum TNF-α significantly correlated with JADAS-27 (r = 0.32, p = 0.03) and CHAQ (r = 0.37, p = 0.01) and negatively with the presence of GG alleles (r = -0.48, p = 0.001). The GG alleles were significantly negatively associated with C-reactive protein (r = -0.32, p = 0.03) with a tendency to negatively correlate with JADAS-27, CHAQ, and JADI-extrarticular (r = -0.28, p = 0.06; r = -0.25, p = 0.09 and r = -0.25, p = 0.09, respectively). There is evidence of a possible influence of the -308 SNP promoter position on the production of TNF-α, the severity of JIA which may consequently influence the response to anti-TNF-α treatment.

Entities:  

Keywords:  308 A/G gene polymorphism; CHAQ; JADAS-27; JADI; JIA; TNF-α

Mesh:

Substances:

Year:  2017        PMID: 28593608     DOI: 10.1007/s10067-017-3719-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

Review 1.  Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.

Authors:  L J Abraham; K M Kroeger
Journal:  J Leukoc Biol       Date:  1999-10       Impact factor: 4.962

2.  Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity.

Authors:  Bronwen Dalziel; Alison K Gosby; Rosemary M Richman; Janet M Bryson; Ian D Caterson
Journal:  Obes Res       Date:  2002-05

Review 3.  Update on the pathogenesis and treatment of systemic idiopathic arthritis.

Authors:  Keith A Sikora; Alexei A Grom
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

4.  Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Authors:  Janneke Anink; Marieke H Otten; Simone L Gorter; Femke H M Prince; Marion A J van Rossum; J Merlijn van den Berg; Philomine A van Pelt; Sylvia Kamphuis; Danielle M C Brinkman; Wijnand A A Swen; Joost F Swart; Nico M Wulffraat; Koert M Dolman; Yvonne Koopman-Keemink; Esther P A H Hoppenreijs; Wineke Armbrust; Rebecca ten Cate; Lisette W A van Suijlekom-Smit
Journal:  Rheumatology (Oxford)       Date:  2013-06-04       Impact factor: 7.580

5.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

Authors:  Alessandro Consolaro; Nicolino Ruperto; Anna Bazso; Angela Pistorio; Silvia Magni-Manzoni; Giovanni Filocamo; Clara Malattia; Stefania Viola; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2009-05-15

6.  Tumor necrosis factor-alpha -308 genotypes influence inflammatory activity and TNF-alpha serum concentrations in children with juvenile idiopathic arthritis.

Authors:  Ana Filipa Mourão; Joana Caetano-Lopes; Paula Costa; Helena Canhão; Maria José Santos; Patrícia Pinto; Iva Brito; Paulo Nicola; João Cavaleiro; José Teles; Artur Sousa; José Melo Gomes; Jaime Branco; José Teixeira da Costa; João Gomes Pedro; Mário Viana de Queiroz; João Eurico Fonseca
Journal:  J Rheumatol       Date:  2009-01-22       Impact factor: 4.666

7.  Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters.

Authors:  N Kutukculer; S Caglayan; F Aydogdu
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 8.  Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis.

Authors:  Flora McErlane; Michael W Beresford; Eileen M Baildam; Wendy Thomson; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2013-04-28       Impact factor: 7.580

9.  Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter.

Authors:  João Eurico Fonseca; João Cavaleiro; José Teles; Elsa Sousa; Valeska L Andreozzi; Marília Antunes; Maria A Amaral-Turkman; Helena Canhão; Ana F Mourão; Joana Lopes; Joana Caetano-Lopes; Pamela Weinmann; Marta Sobral; Patrícia Nero; Maria J Saavedra; Armando Malcata; Margarida Cruz; Rui Melo; Araceli Braña; Luis Miranda; José V Patto; Anabela Barcelos; José Canas da Silva; Luís M Santos; Guilherme Figueiredo; Mário Rodrigues; Herberto Jesus; Alberto Quintal; Teresa Carvalho; José A Pereira da Silva; Jaime Branco; Mário Viana Queiroz
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 10.  Current developments in the use of biomarkers for juvenile idiopathic arthritis.

Authors:  Chantal L Duurland; Lucy R Wedderburn
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.